Perjeta (Pertuzumab)

02:42 EST 20th January 2019 | BioPortfolio

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Understanding HER2-positive Breast Cancer

All cells have HER2 receptors, including healthy cells and cancer cells. In HER2-positive breast cancer, tumor cells have more HER2 receptors than normal. Too much HER2 makes these cancer cells grow and divide too rapidly.

Cancer treatments called HER2-targeted therapies have been developed to target the HER2 receptor.

PERJETA - HER2-targeted therapies

Targeted therapies are designed to search for and attack specific parts of the cancer cell that cause it to grow and multiply. A few therapies have been developed to target the HER2 receptor. These targeted therapies, such as PERJETA and Herceptin (trastuzumab), aim to fight cancer cells that have too much HER2, and are designed to cause less harm to healthy cells. Since healthy cells also have HER2 (just not as much), HER2-targeted therapies can also affect healthy cells, which may cause side effects, some of which can be serious. PERJETA is a targeted therapy, like Herceptin, but it works to fight cancer in a different way.

For further information open -

Quick Search


review and buy Perjeta (Pertuzumab) market research data and corporate reports here